@article{Gasser2014,
abstract = {A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 $\mu$g of LSD (n = 8) or 20 $\mu$g of LSD with an open-label crossover to 200 $\mu$g of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.},
archivePrefix = {arXiv},
arxivId = {arXiv:1011.1669v3},
author = {Gasser, Peter and Holstein, Dominique and Michel, Yvonne and Doblin, Rick and Yazar-Klosinski, Berra and Passie, Torsten and Brenneisen, Rudolf},
doi = {10.1097/NMD.0000000000000113},
eprint = {arXiv:1011.1669v3},
isbn = {0000000000000},
issn = {1539-736X},
journal = {J. Nerv. Ment. Dis.},
keywords = {Adult,Anxiety,Anxiety Disorders,Anxiety Disorders: drug therapy,Anxiety Disorders: etiology,Anxiety Disorders: therapy,Anxiety: drug therapy,Anxiety: etiology,Anxiety: therapy,Combined Modality Therapy,Cross-Over Studies,Female,Follow-Up Studies,Humans,Lysergic Acid Diethylamide,Lysergic Acid Diethylamide: administration {\&} dosag,Lysergic Acid Diethylamide: adverse effects,Lysergic Acid Diethylamide: pharmacology,Male,Middle Aged,Neoplasms,Neoplasms: psychology,Pilot Projects,Placebos,Psychiatric Status Rating Scales,Psychotherapy,Psychotherapy: methods,Serotonin Antagonists,Serotonin Antagonists: administration {\&} dosage,Serotonin Antagonists: adverse effects,Serotonin Antagonists: pharmacology,Treatment Outcome},
number = {7},
pages = {513--20},
pmid = {24594678},
title = {{Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.}},
url = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086777{\&}tool=pmcentrez{\&}rendertype=abstract},
volume = {202},
year = {2014}
}

{"_id":"gDmFrj5XFmxhJ49Gy","bibbaseid":"gasser-holstein-michel-doblin-yazarklosinski-passie-brenneisen-safetyandefficacyoflysergicaciddiethylamideassistedpsychotherapyforanxietyassociatedwithlifethreateningdiseases-2014","downloads":0,"creationDate":"2017-08-29T20:29:02.543Z","title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.","author_short":["Gasser, P.","Holstein, D.","Michel, Y.","Doblin, R.","Yazar-Klosinski, B.","Passie, T.","Brenneisen, R."],"year":2014,"bibtype":"article","biburl":"https://mind-foundation.org/wp-content/uploads/2017/09/04.09.2017 ASC-Study-Monitor.bib","bibdata":{"bibtype":"article","type":"article","abstract":"A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 $\\mu$g of LSD (n = 8) or 20 $\\mu$g of LSD with an open-label crossover to 200 $\\mu$g of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.","archiveprefix":"arXiv","arxivid":"arXiv:1011.1669v3","author":[{"propositions":[],"lastnames":["Gasser"],"firstnames":["Peter"],"suffixes":[]},{"propositions":[],"lastnames":["Holstein"],"firstnames":["Dominique"],"suffixes":[]},{"propositions":[],"lastnames":["Michel"],"firstnames":["Yvonne"],"suffixes":[]},{"propositions":[],"lastnames":["Doblin"],"firstnames":["Rick"],"suffixes":[]},{"propositions":[],"lastnames":["Yazar-Klosinski"],"firstnames":["Berra"],"suffixes":[]},{"propositions":[],"lastnames":["Passie"],"firstnames":["Torsten"],"suffixes":[]},{"propositions":[],"lastnames":["Brenneisen"],"firstnames":["Rudolf"],"suffixes":[]}],"doi":"10.1097/NMD.0000000000000113","eprint":"arXiv:1011.1669v3","isbn":"0000000000000","issn":"1539-736X","journal":"J. Nerv. Ment. Dis.","keywords":"Adult,Anxiety,Anxiety Disorders,Anxiety Disorders: drug therapy,Anxiety Disorders: etiology,Anxiety Disorders: therapy,Anxiety: drug therapy,Anxiety: etiology,Anxiety: therapy,Combined Modality Therapy,Cross-Over Studies,Female,Follow-Up Studies,Humans,Lysergic Acid Diethylamide,Lysergic Acid Diethylamide: administration & dosag,Lysergic Acid Diethylamide: adverse effects,Lysergic Acid Diethylamide: pharmacology,Male,Middle Aged,Neoplasms,Neoplasms: psychology,Pilot Projects,Placebos,Psychiatric Status Rating Scales,Psychotherapy,Psychotherapy: methods,Serotonin Antagonists,Serotonin Antagonists: administration & dosage,Serotonin Antagonists: adverse effects,Serotonin Antagonists: pharmacology,Treatment Outcome","number":"7","pages":"513–20","pmid":"24594678","title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.","url":"http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086777&tool=pmcentrez&rendertype=abstract","volume":"202","year":"2014","bibtex":"@article{Gasser2014,\nabstract = {A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 $\\mu$g of LSD (n = 8) or 20 $\\mu$g of LSD with an open-label crossover to 200 $\\mu$g of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.},\narchivePrefix = {arXiv},\narxivId = {arXiv:1011.1669v3},\nauthor = {Gasser, Peter and Holstein, Dominique and Michel, Yvonne and Doblin, Rick and Yazar-Klosinski, Berra and Passie, Torsten and Brenneisen, Rudolf},\ndoi = {10.1097/NMD.0000000000000113},\neprint = {arXiv:1011.1669v3},\nisbn = {0000000000000},\nissn = {1539-736X},\njournal = {J. Nerv. Ment. Dis.},\nkeywords = {Adult,Anxiety,Anxiety Disorders,Anxiety Disorders: drug therapy,Anxiety Disorders: etiology,Anxiety Disorders: therapy,Anxiety: drug therapy,Anxiety: etiology,Anxiety: therapy,Combined Modality Therapy,Cross-Over Studies,Female,Follow-Up Studies,Humans,Lysergic Acid Diethylamide,Lysergic Acid Diethylamide: administration {\\&} dosag,Lysergic Acid Diethylamide: adverse effects,Lysergic Acid Diethylamide: pharmacology,Male,Middle Aged,Neoplasms,Neoplasms: psychology,Pilot Projects,Placebos,Psychiatric Status Rating Scales,Psychotherapy,Psychotherapy: methods,Serotonin Antagonists,Serotonin Antagonists: administration {\\&} dosage,Serotonin Antagonists: adverse effects,Serotonin Antagonists: pharmacology,Treatment Outcome},\nnumber = {7},\npages = {513--20},\npmid = {24594678},\ntitle = {{Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.}},\nurl = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086777{\\&}tool=pmcentrez{\\&}rendertype=abstract},\nvolume = {202},\nyear = {2014}\n}\n","author_short":["Gasser, P.","Holstein, D.","Michel, Y.","Doblin, R.","Yazar-Klosinski, B.","Passie, T.","Brenneisen, R."],"key":"Gasser2014","id":"Gasser2014","bibbaseid":"gasser-holstein-michel-doblin-yazarklosinski-passie-brenneisen-safetyandefficacyoflysergicaciddiethylamideassistedpsychotherapyforanxietyassociatedwithlifethreateningdiseases-2014","role":"author","urls":{"Paper":"http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4086777&tool=pmcentrez&rendertype=abstract"},"keyword":["Adult","Anxiety","Anxiety Disorders","Anxiety Disorders: drug therapy","Anxiety Disorders: etiology","Anxiety Disorders: therapy","Anxiety: drug therapy","Anxiety: etiology","Anxiety: therapy","Combined Modality Therapy","Cross-Over Studies","Female","Follow-Up Studies","Humans","Lysergic Acid Diethylamide","Lysergic Acid Diethylamide: administration & dosag","Lysergic Acid Diethylamide: adverse effects","Lysergic Acid Diethylamide: pharmacology","Male","Middle Aged","Neoplasms","Neoplasms: psychology","Pilot Projects","Placebos","Psychiatric Status Rating Scales","Psychotherapy","Psychotherapy: methods","Serotonin Antagonists","Serotonin Antagonists: administration & dosage","Serotonin Antagonists: adverse effects","Serotonin Antagonists: pharmacology","Treatment Outcome"],"downloads":0},"search_terms":["safety","efficacy","lysergic","acid","diethylamide","assisted","psychotherapy","anxiety","associated","life","threatening","diseases","gasser","holstein","michel","doblin","yazar-klosinski","passie","brenneisen"],"keywords":["adult","anxiety","anxiety disorders","anxiety disorders: drug therapy","anxiety disorders: etiology","anxiety disorders: therapy","anxiety: drug therapy","anxiety: etiology","anxiety: therapy","combined modality therapy","cross-over studies","female","follow-up studies","humans","lysergic acid diethylamide","lysergic acid diethylamide: administration & dosag","lysergic acid diethylamide: adverse effects","lysergic acid diethylamide: pharmacology","male","middle aged","neoplasms","neoplasms: psychology","pilot projects","placebos","psychiatric status rating scales","psychotherapy","psychotherapy: methods","serotonin antagonists","serotonin antagonists: administration & dosage","serotonin antagonists: adverse effects","serotonin antagonists: pharmacology","treatment outcome","lsd","anxiety disorder","hallucinogen","psychedelic","psycholytic therapy"],"authorIDs":[],"dataSources":["nZgrskreN65H4K49p"]}